MicroRNAs and esophageal squamous cell carcinoma

doi:10.3760/cma.j.issn.1673-422X.2016.11.015

Abstract

Chen Jun, Li Jie. MicroRNAs and esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2016, 43(11): 858-860.

［1］ Nie J, Ge X, Geng Y, et al. miR34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting yin yang1［J］. Oncol Rep, 2015, 34(1): 311-317. DOI: 10.3892/or.2015.3962. ［2］ Zhou L, Zhang X, Li Z, et al. Association of a genetic variation in a miR191 binding site in MDM4 with risk of esophageal squamous cell carcinoma［J］. PLoS One, 2013, 8(5): e64331. DOI: 10.1371/journal.pone.0064331. ［3］ Yu T, Cao R, Li S, et al. MiR130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells［J］. BMC Cancer, 2015, 15(1): 29. DOI: 10.1186/s1288501510315. ［4］ Tanaka Y, Kamohara H, Kinoshita KA, et al. Clinical impact of serum exosomal microRNA21 as a clinical biomarker in human esophageal squamous cell carcinoma［J］. Cancer, 2013, 119(6): 1159-1167. DOI: 10.1002/cncr.27895. ［5］ Matsushima K, Isomoto H, Yamaguchi N, et al. MiRNA205 modulates cellular invasion and migration via regulating zinc finger Ebox binding homeobox 2 expression in esophageal squamous cell carcinoma cells［J］. J Transl Med, 2011, 9(1): 30. DOI: 10.1186/1479-5876-9-30. ［6］ Li S, Qin X, Li Y, et al. MiR133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4［J］. Am J Transl Res, 2015, 7(8): 1390-1403. ［7］ Dong W, Shen R, Cheng S. Reduction of TIP30 in esophageal squamous cell carcinoma cells involves promoter methylation and microRNA10b［J］. Biochem Biophys Res Commun, 2014, 453(4): 772-777. DOI: 10.1016/j.bbrc.2014.10.016. ［8］ Maroof H, Salajegheh A, Smith RA, et al. Role of microRNA34 family in cancer with particular reference to cancer angiogenesis［J］. Exp Mol Pathol, 2014, 97(2): 298-304. DOI: 10.1016/j.yexmp.2014.08.002. ［9］ Zhang CN, Wang C, Chen X, et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma［J］. Clin Chem, 2010, 56(12): 1871-1879. DOI: 10.1373/clinchem.2010.147553. ［10］ Wu C, Wang C, Guan X, et al. Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma［J］. PLoS One, 2014, 9(3): e92292. DOI: 10.1371/journal.pone.0092292. ［11］ Li C, Li DC, Che SS, et al. The decreased expression of miR625 predicts poor prognosis of esophageal squamous cell carcinoma［J］. Int J Clin Exp Med, 2015, 8(6): 9560-9564. ［12］ Wu C, Li M, Hu C, et al. Clinical significance of serum miR223, miR25 and miR375 in patients with esophageal squamous cell carcinoma［J］. Mol Biol Rep, 2014, 41(3): 1257-1266. DOI: 10.1007/s11033-013-2970-z. ［13］ Zhao L, Bode AM, Cao Y, et al. Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity［J］. Carcinogenesis, 2012, 33(11): 2220-2227. DOI: 10.1093/carcin/bgs235. ［14］ Wu S, Wang X, Chen JX, et al. Predictive factors for the sensitivity of radiotherapy and prognosis of esophageal squamous cell carcinoma［J］. Int J Radiat Biol, 2014, 90(5): 407-413. DOI: 10.3109/09553002.2014.894649. ［15］ Wang XC, Zhang ZB, Wang YY, et al. Increased miRNA22 expression sensitizes esophageal squamous cell carcinoma to irradiation［J］. J Radiat Res, 2013, 54(3): 401-408. DOI: 10.1093/jrr/rrs113. ［16］ Zhou S, Ye W, Ren J, et al. MicroRNA381 increases radiosensitivity in esophageal squamous cell carcinoma［J］. Am J Cancer Res, 2015, 5(1): 267-277. ［17］ Imanaka Y, Tsuchiya S, Sato F, et al. MicroRNA141 confers resistance to cisplatininduced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma［J］. J Hum Genet, 2011, 56(4): 270276. DOI: 10.1038/jhg.2011.1. ［18］ Hummel R, Sie C, Watson DI, et al. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines［J］. World J Gastroenterol, 2014, 20(40): 14904-14912. DOI: 10.3748/wjg.v20.i40.14904. ［19］ Zhang H, Li M, Han Y, et al. Downregulation of miR27a might reverse multidrug resistance of esophageal squamous cell carcinoma［J］. Dig Dis Sci, 2010, 55(9): 2545-2551. DOI: 10.1007/s10620-009-1051-6.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[3]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[6]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong. Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2023, 50(2): 76-81.
[9]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750.
[10]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.
[11]	Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian. Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN₊ esophageal squamous cell carcinoma patients [J]. Journal of International Oncology, 2022, 49(6): 334-339.
[12]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing. MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2 [J]. Journal of International Oncology, 2022, 49(4): 193-198.
[13]	Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong. Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 199-205.
[14]	Zhou Jianfeng, Wang Tiejun. Targeted therapy and immunotherapy of esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 237-242.
[15]	Liu Jia, Ge Xiaolin, Di Xiaoke, Shi Yujing, Zeng Yuting. Efficacy analysis of Xiyanping injection on prevention of radioactive esophagitis [J]. Journal of International Oncology, 2022, 49(3): 146-150.

MicroRNAs and esophageal squamous cell carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments